|Publication number||WO1991000915 A1|
|Publication date||24 Jan 1991|
|Filing date||27 Jun 1990|
|Priority date||11 Jul 1989|
|Also published as||EP0482125A1|
|Publication number||PCT/1990/3663, PCT/US/1990/003663, PCT/US/1990/03663, PCT/US/90/003663, PCT/US/90/03663, PCT/US1990/003663, PCT/US1990/03663, PCT/US1990003663, PCT/US199003663, PCT/US90/003663, PCT/US90/03663, PCT/US90003663, PCT/US9003663, WO 1991/000915 A1, WO 1991000915 A1, WO 1991000915A1, WO 9100915 A1, WO 9100915A1, WO-A1-1991000915, WO-A1-9100915, WO1991/000915A1, WO1991000915 A1, WO1991000915A1, WO9100915 A1, WO9100915A1|
|Inventors||Laurens J. Mets|
|Applicant||Biotechnology Research & Development Corporation|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (1), Non-Patent Citations (2), Referenced by (84), Classifications (9), Legal Events (7)|
|External Links: Patentscope, Espacenet|
AEROSOL BEAM MICROINJECTOR
The present invention relates to the introduction of exogenous material into a living cell, tissue, or species, and more particularly, to apparatus and methods for microinjecting exogenous materials into a living cell, tissue, or species.
The genetic transformation of cells using the technigues of genetic engineering has grown dramatically over the last few years. Generally, genetic engineering involves the introduction of foreign DNA into a host cell to change or "transform" the host cell. When successfully done, the genes carried by the foreign DNA are expressed in the host cell, and thus, the last cell is transformed.
Genetically transformed cells, tissues, or species are of great commercial value in research, agriculture, and medicine. For example, human insulin is presently being produced by bacteria which have been genetically engineered. Human insulin is now available in commercial guantities, and has benefitted millions of diabetics throughout the world. In addition, several plant species have been genetically engineered to produce more crop, become more resistant to disease, and grow in less hospitable climates and soils.
Because of the commercial and social importance of genetic engineering, a plurality of methods for transferring foreign genes into a recipient cell have been developed for both procaryotic and eucaryotic cells. These gene transfer techniques are routinely used in laboratories throughout the world to genetically transform living cells, tissues and species. However, despite the existence of these diverse transformation techniques, the effective stable transfer of genes remains an obstacle in many fields of research. One technique for gene transfer is cell fusion. Cell fusion has been applied to both animal and plant cell cultures. Cell fusion techniques integrate the genetic information of two different cells in one. In plant cell cultures, cell walls are dissolved and the naked protoplasts are fused together, forming a new cell. The descendants of the new fused cell express certain characteristics of both the original (parent) cells. However, researchers have no means of predicting what characteristics will be expressed in the progeny. Thus, the results obtained using cell fusion techniques are unpredictable and are generally not reproducible.
In animal cell cultures, hybridomas are the cell fusion product of antibody-secreting cells and "immortal" cells (myelomas) . Hybridomas are used in medicine and research to produce monoclonal antibodies. Hybridomas, like the plant cell fusion products, may react unpredictably, and are expensive to produce and maintain.
Electroporation is another general method for introducing foreign DNA into cells. This procedure involves the exposure of a suspension of cells and fragments of foreign DNA to a pulsed high-voltage electrical discharge. This electrical discharge creates holes or pores in the cell membrane through which DNA fragments diffuse. Upon cessation of the electrical discharge, the pores in the cell membrane close, capturing any DNA fragments which have diffused into the cell. However, a major drawback in using electroporation to introduce DNA into living cells is the necessity prior to a successful transformation, to determine empirically optimum values for a wide variety of parameters for each cell line in question. These parameters include voltage, capacitance, pulse time composition and resistance of electroporation medium, state of cell growth prior to electroporation, concentration of DNA, temperature, and cell density. Also, present methods for applying electroporation to cells with walls, such as plant cells, require removing the walls prior to electroporation.
These protoplasts must then regenerate their walls before they can divide and be regenerated into intact plants. Since not many plants can yet be regenerated from protoplasts, this requirement limits applicability of electroporation.
Viral infection is also an efficient means of transferring foreign DNA into some cells. However, viruses are difficult to work with, and since a particular virus will only infect certain cells, the technique is not applicable to the broad spectrum of living cells, tissue, or species. Further, some virus may in fact be hazardous to the technicians working with them or to the environment.
The most common and effective method for transferring genes into plant cells involves conjugal transfer from living bacteria, primarily Aσrobacterium tumefacient and Aσrobacterium rhizocrenes. The DNA to be transferred is first engineered into plasmids derived from the bacterial Ti plasmid, and the bacteria are then incubated in culture with the recipient plant cells. The cultured, transformed cells must then be regenerated into genetically homogeneous plants. This method is limited to plants susceptible to Agrobacterium infection (principally dicots) that can be regenerated from cultures. Still another technique for gene transfer is micropipette microinjection. In micropipette microinjection, DNA or other exogenous materials, are stably introduced into a living cell by microinjecting the material directing into the nuclei of the cell. Typically, a glass micropipette having a diameter of from about 0.1 to about 0.5 microns is inserted directly into the nucleus of the cell. Through the bore of the micropipette exogenous material, such as DNA, is injected. An experienced, skilled technician can inject from about 500 to about 1000 cells per hour. Presently, however, micropipette microinjection requires some fairly sophisticated and expensive equipment, such as, a micropipette puller for making the needles, and a micromanipulator to position the needles correctly for injection. Moreover, extensive practice and training is needed for a technician to master this tedious technique. Micropipette microinjection is an effective method of gene transfer; however, because of the relatively small number of cells that may be transformed in any one experiment, the cost of the elaborate equipment necessary, and the level of skill needed to perform the procedure, microinjection using micropipettes is not a method of gene transfer available to the vast majority of researchers in the field.
Although a number of gene transfer techniques are available; presently, no prior technique provides a safe, fast, effective, inexpensive, and reproducible method for genetically transforming a broad spectrum of living material regardless of cell, tissue or species type. Present methods are either expensive, slow, or yield results which are not reproducible. Moreover, some methods, such as the use of infectious agents, may even be hazardous to the researcher or the environment. Accordingly, a new apparatus and method for transforming cells, tissue, or species is needed.
Advantages of the invention will become apparent upon reading the following detailed description and upon reference to the drawings in which:
FIG. l is a schematic illustration of the aerosol beam microinjector;
Fig. 2 is a schematic illustration of an aerosol beam microinjector including a drying tube and means for providing sheath flow; and
Fig. 3 is a schematic illustration of an aerosol beam microinjector additionally including means for adjusting the diameter of the injected droplet.
The present invention is directed to an apparatus an methods for the introduction of exogenous materials, for example foreign DNA, into a variety of recipient cells. It is believed that the present invention should have a profound effect upon the variety of plants, and animals, that will become amenable to direct genetic manipulation.
The present invention uses aerosol beam technology t accelerate either wet or dry aerosol particles to speeds enabling the particles to penetrate living cells upon impact therewith. Aerosol particles suspended in a inert gas can be accelerated to a very high velocity during the jet expansion of the gas as it passes from a region of higher gas pressure to a region of lower gas pressure through a small orifice. This acceleration process has been well-studied and used for many years in the field of aerosol physics. The accelerated droplets may be positioned to impact a preferred target, for example, a plant or animal cell. When the particles include DNA or other macromolecules, the macromolecules are introduced into the cells. The droplets may be constructed as droplets of a sufficiently small size so that the cells survive the penetration. Once introduced into the target cell the macromolecules can elicit biological effects. This effect will depend on the specific properties of the macromolecules and the nature of the recipient cells. For example, DNA may be introduced into the target cell, thereby altering the genetic make-up of the cell. Because the method of introduction is a physical one, the biological barriers that restrict the application of other DNA transfer methods to a few plant species and a few cell types are not present. The size, kinetic energy and beam intensity of the aerosol stream can be precisely controlled over a wide range, and hence may be successful in penetrating and transforming a wide variety of cell types. In addition, the use of a continuous aerosol beam will permit the treatment of a large number of cells in the course of any single treatment. Thus, the inventive method should be applicable to a wide range of plant species and cell types that have proved in the past to be quite impervious to standard methods of genetic engineering. According to a preferred embodiment, the apparatus and methods of the present invention are utilized tp produce a transformed line of plants. Aerosol particles^comprising exogenous genetic material are produced and accelerated to a speed enabling them to penetrate and enter into a living plant cell upon impact therewith. The cells are thereafter cultured to grow a plant. The progeny of the plant are subsequently screened using techniques well known to one skilled in the art of plant genetics, for transformed progeny.
According to a preferred embodiment, the apparatus and methods of the present invention are utilized to produce transformed maize plants. Cells from an embryogenic culture of an alcohol dehydrogenese-deficient (adh~) recipient plant are preferably plated on an agar surface of osmotically supportive medium. They would then be placed in the chamber on the target positioning device for treatment with aerosol carrying a mild type ahd gene on a plasmid. The apparatus shown in FIG. 3 is preferably used. The DNA plasmid would be adjusted to 3mMMyCl2 and rapidly mixed with 100% ethanol to yield 95% final ethanol concentration. The concentration of DNA would be such that each droplet of primary aerosol generated in the nebulizer contains an average of 2-3 plasmid molecules (about 1013 molecule per ml of final ethanol solutions) . The primary aerosol, generated in the nebulizer would then be dried and the ethanol vapor trapped in the diffusion dryer. The DNA aerosol stream would be humidified with 5x10 g water vapor per primary aerosol particles, and the mixture cooled to 0°c. to generate a 0.5 - 1.0 mm diameter uniform size aerosol droplets. These would be accelerated by the expansion of the N2 inert gas through a 250 mm orifice to strike the target cells 1.5 cm away from the orifice. The injected cells would then be cultured and tested by cytological staining for the presence of adh activity in the cells. An appropriate number of cells would be grown into plants and for the tested for the presence of the transforming DNA and for function of the adh gene.
A further preferred embodiment of the present invention utilizes the apparatus and methods of the present invention genetic transformation of maize pollen. Pollen from a recipient variety deficient in adh would be plated on osmotically supportive agar medium and placed in the device shown in FIG. 3. Transforming DNA would be formed into a primary aerosol of 95% ethanol as described for embryogenic cell transformation, and then dried as set forth above. In this case, the aerosol stream would be humidified with perfluorocarbon vapor (3M or Air Products) at a density of 8xl0~12 g per primary aerosol droplet. Condensation at 0βC would then generate 2 micron uniform diameter droplets. These would be accelerated with the inert gas expansion to impact the pollen grains. After 1 hr recovery period, the pollen would be transferred to silks of adh deficient corn plants. The seeds obtained would be planted and transformed plants recognized by the presence of adh-stainable pollen in samples from the mature plants.
Aerosol particles are formed by aerosolizing solutions containing the macromolecule. Preferably, excess solvent is subsequently evaporated from the aerosol particles to reduce projectile size, thus increasing the rate of survival in the impacted target cells. When the aerosol particles are constructed as droplets the density of the final droplets is important, since less dense droplets may cause less damage to some target cells when they penetrate, while, on the other hand, more dense droplets may be required to penetrate certain target cells. Accordingly, the present invention provides means to modify both the size and density of the droplets as required for penetrating different cells. According to one preferred embodiment, the density of the droplets is from about 0.8 to about 8 gram/cc, and most preferably about 2 grams/cc. The density is modified by the addition of solutes, for example colloidal gold, to the solution prior to forming an aerosol or by using solvents, such as perfluorocarbons, that have different densities. Further, the apparatus of the present invention may be modified to include means for removing excess solvent, thus reducing droplet size, or adding additional solvent to the droplet, thus increasing the size of the droplet. Figs. 1, 2 and 3, illustrate several embodiments of an aerosol beam microinjector of the present invention. Each Fig. will be discussed in detail when appropriate, otherwise the following discussion is applicable to each FIG. Compressed inert gas is filtered as it passes through a tubing 1 into the inlet 3 of a nebulizer 5 disbursing aerosol particles (a suspension of solvent and solute) into the inert gas to form an aerosol. The source of the compressed gas 6 preferably provides a gas pressure of from about 10 to about 100 psi at the inlet 3.
However, the compressed gas most preferably provides about 30 psi at the inlet 3. Preferably, the projectiles (droplets of solvent and suspended particulate matter) have mass mean diameters of from about 0.1 to about 2 microns. The present inventor has determined that projectiles having diameters outside of this range are not preferable in the practice of the present invention. Projectiles having a diameter of greater than about 2 microns were found to cause an unacceptable level of cell death following impact, while projectiles having a diameter of below about 0.1 microns were unable to efficiently penetrate into the target cell.
The aerosol exits the nebulizer 5 through an outlet 7. The present inventor has determined that it is preferable to dissipate the pressure of the compressed gas prior to the acceleration of the aerosol. This is accomplished, in one preferred embodiment, by venting the aerosol to the outside atmosphere. As shown in Fig. 1, 2, and 3, the outlet 7 and the inlet 9 of tubing 11 do not abut each other, but are rather, positioned in a close proximity to each other. This arrangement allows the pressure of the compressed gas to dissipate, while furthe allowing the aerosol to enter inlet 9 of tubing 11. According to a further preferred embodiment not shown in the FIGS, the aerosol is discharged from the outlet 7 int -10-
a non-restrictive enclosure, such as a non-reactive plastic bag. Once the gas pressure from the compressed gas has been alleviated, a portion of the aerosol is drawn into the inlet 9 of a tubing 11. The aerosol is drawn 5 into the tubing 11 by a negative or low gas pressure (a gas pressure below that of the surrounding atmosphere) . This negative pressure is preferably about l atmosphere and is created within the tubing 11 by a high-volume vacuum pump 13 in communication with an air-tight vacuum
10 housing 15 which is functionally connected to the outlet 16 of the tubing 11. If the aerosol is being discharged into the atmosphere, the inlet 9 of the tubing 11 is preferably positioned in a relatively close proximity to the nebulizer outlet 7. Preferably, this distance is
15 about one-half inch.
Referring specifically to Fig. 1, Fig. 1 shows the tubing 11 entering the housing 15. Fig. 1 shows the tubing outlet 16 including a nozzle 17 through which the 20 inert gas and the aerosol eventually passes through to reach the vacuum housing 15.
Returning, generally, to Figs, l, 2, and 3, the pressure within the tubing 11 and correspondingly within
25 the vacuum housing 15 may be regulated by the pumping speed of the pump 13, the flow resistance caused by the nozzle 17, or the evaporation of solvent from samples within the vacuum housing 15. The aerosol is drawn through the length of tubing 11 to the nozzle 17. The
30 nozzle 17 preferably has an aperture diameter of from 100 to 300 microns. The present inventor has determined that the most preferred aperture diameter of nozzle 17 is about 200 microns. The aerosol is thereafter drawn through nozzle 17 and into the vacuum housing 15.
35 The passage of the aerosol from the relatively high gas pressure area within tubing 11 into the relatively low gas pressure area within the vacuum housing 15 causes the inert gas to dramatically expand. The rapid expansion of the inert gas through the nozzle 17 causes the aerosol particles to accelerate. For example, when nitrogen is used as the inert gas, it has been determined that the aerosol particles can be accelerated up to speeds of from about 400 to about 800 meters/second. Further, if helium is used as the inert gas, the aerosol particles may be accelerated up to speeds of about 2000 meters/second. The vacuum housing 15 is continuously evacuated by the pump 13 to remove the inert gas and keep the pressure in the housing below the gas pressure in the tubing 11. According to one preferred embodiment, the gas pressure in housing 15 is from about 0.01 to about 0.05 atmospheres, and most preferably about 0.01 atmospheres.
When the inert gas is expanded and the aerosol is accelerated, an aerosol beam is generated. In the vacuum housing 15 the inert gas portion of the aerosol is expanded and removed and accelerated aerosol particles follow straight line trajectories. Aerosol beams are thus composed of accelerated isolated particles and droplets (hereinafter referred to as simply projectiles) moving on well defined, straight line trajectories at speeds up to 2000 meters/seconds.
Referring now to Fig. 2, Fig. 2 illustrates an aerosol beam microinjector including means for manipulating the size of the projectiles, and means for focusing the aerosol flow through the nozzle 17. As the aerosol is drawn through tubing 11 it is drawn into a drying tube 23. Drying tube 23 contains a desiccant which traps solvent evaporated from the surface of the solute, thus decreasing the diameter of the projectile. The flow -12-
rate of the aerosol, the length of the drying tube, the solvent used, and the desiccant contained in the drying tube, may all be modified to remove varying amounts of solvent from the aerosol. According to one preferred 5 embodiment, the drying tube 23 has an internal diameter of about one-half inch and an effective length of about 60 cm. The drying tube 23 contains silica gel as a desiccant. The silica gel surrounds a central channel formed by a cylinder of 20 mesh stainless steel screen. 10 Commercial drying tubes similar to the drying tube described above and useful in the practice of the present invention are available from TSI, Inc., Model 3062 Diffusion Dryer.
15 Once treated, the aerosol continues through tubing
11. The aerosol is discharged from outlet 7 of tubing 11 and into the precise center of a laminar flow of dry, filtered inert gas. The aerosol is thus entrained in the center of a gas stream moving up to and through the nozzle
20 17. This is preferable because it increases the average velocity of the projectiles, focuses the aerosol beam, and prevents nozzle clogging. When a gas flows through a nozzle 17, the velocity profile is never constant over the entire cross section. The particles nearest the nozzle
25 wall will have velocities substantially less than particles traveling in the center of the beam. Further, the radial expansion of the carrier gas will cause the aerosol beam to expand radially outward. Particles near the beam center are not influenced by this radial
30 expansion but particles at increasing radii obtain an increasing radial velocity component. Accordingly, Fig. 2 illustrates an aerosol beam microinjector which includes means for reducing the radial expansion of the aerosol beam and maintaining a substantially uniform velocity
35 through the cross section of the beam. Fig. 2 shows a piping 19 drawing filtered inert gas into its length and transporting that gas to the inlet 21 of the sheath flow piping 24. The inert gas, which accounts for the sheath flow, enters the piping 19 with no positive pressure and is drawn from a non-restrictive reservoir of inert gas or from the outside atmosphere when the inert gas is released from a source 26 in the immediate area of the inlet 25 of piping 19, as shown in Fig. 2. The aerosol is discharged from tubing 11 into the center of the sheath flow piping 24. The aerosol is entrained in the laminar flow of the inert gas in the sheath flow piping 24. The laminar flow focuses the aerosol through the center of the nozzle 17, thus allowing the aerosol to maintain a substantially uniform velocity across its cross section. The laminar flow also reduces beam spreading so that a more focused beam is obtained. According to one preferred embodiment the laminar flow accounts for 50% of the flow through the nozzle 17.
Referring to Fig. 3, Fig. 3 illustrates an aerosol beam microinjector having additional means to control particle size. As in the apparatus illustrated in Fig. 2, the apparatus of Fig. 3 includes a drying tube 23. However, in the apparatus of Fig. 3 the drying tube removes substantially all the solvent from the aerosol. Thus, the aerosol exiting the drying tube 23 through the tubing 11 is comprised substantially of dry solute. The solute is discharged from the tubing 11 into a channel 27 of a gas reheater 29. In addition to the dry solute solvent, solvent saturated carrier gas is discharged into the channel 27.
The solvent saturated inert gas is produced in the vapor saturator 31 and is transported through the piping 19 to the channel 27 of the reheater 29. Filtered dry inert gas is drawn from a source 26 into the piping 19, a discussed for the apparatus of Fig. 2. The inert gas thereafter enters the vapor saturator 31, wherein solvent vapor is added to the inert gas to the point of saturation. The vapor saturator 31 is preferably constructed to contain solvent moistened fibrous material forming a central channel 33. Surrounding the solvent- moistened material is preferably an aluminum block 28 heated to a desired temperature with resistive heaters 30. Preferably, this temperature is from about 50 to about 100° C. The heat causes the solvent moistened material to release solvent vapor which is entrained by the inert gas. Although this is a preferred construction for the vapor saturator 31, other means to saturate the inert gas with solvent vapor may be utilized in the practice of the present invention.
The solvent-saturated inert gas is discharged from the vapor saturator 31 into piping 20 which communicates with channel 27 of the reheater 29. The dry aerosol is discharged from tubing 11 also into the reheater 29. The reheater 29 heats the dry aerosol and the solvent- saturated inert gas to a constant temperature. This facilitates the diffusion and mixing of the vapor- saturated inert gas and the dry aerosol particles. Preferably, the resulting mixture is heated to about 50 C.
From the channel 27 of the reheater 29 the solvent- saturated inert gas and the dry aerosol particles move to a vapor condenser 35. The vapor condenser 35 is preferably constructed as having a central channel 37 wherein by reducing the temperature, the solvent vapor is condensed onto the aerosol particles. Depending on the temperature within the channel 37, the amount of solvent condensed may be controlled. Thus, the projectile size may be precisely controlled. According to one embodiment, the vapor condenser 35 includes Lapeltier Coolers, obtained from Marlow Industries. The vapor condenser outlet 39 includes the nozzle 17, and is positioned within the vacuum housing 15.
Referring again to Figs. 1, 2, and 3, placed in the path of these projectiles is the target support platform 41. The target support platform 41 is a substantially horizontal surface capable of supporting target cells thereon and being preferably moveable along the X, Y and Z axis. According to the most preferred embodiment, the target support platform 19 is provided with, supported by, and affixed to a motorized positioning member which enables it to be positioned either closer or farther away from the nozzle 17. Through experimentation, the inventor has determined that the target support platform 41 is preferably positioned about 1.5 cm from the nozzle 17. However, this distance may be varied depending on the specific application. For example, it has been determined that the greater the distance the target support platform 41 is from the nozzle 17 the slower the impact speed of the projectiles. This is due to the background pressure in the vacuum housing 15 reducing the speed of the projectiles as they travel through the housing 15. According to the most preferred embodiment, the target support platform 41 is rotated and is moved by the positioning member along one linear axis 43. This allows for a biological sample placed on the target support platform 41 to be impacted throughout its entirety by projectiles. The present inventors had determined that an effective rate of rotation about axis 43 is 40 rpm and that an effective rate of simultaneous linear advance along axis 43 is 333 microns per revolution. This allows the entirety of a biological sample of approximately 5x7 centimeters to be impacted (hereinafter referred to as scanned) in three to four minutes. Preferable inert gases utilized in the practice of the present invention are filtered compressed inert gas. A preferable carrier gas useful in the practice present invention is one gas selected from the group of gases consisting of carbon dioxide, room air, hydrogen, helium, and nitrogen. However, it should be noted, that any compressed gas substantially nontoxic to living materials may be utilized in a practice of the present invention. The source of the carrier gas 6 is a source of gas capable of generating a gas pressure of 30 pounds per square inch at the inlet 3 of the nebulizer 7. Preferred sources of compressed gas are compressed gas cylinder, and laboratory electrolytic cell gas generators.
The nebulizer 5 utilized in the practice of the present invention may be any nebulizer 5 which produces aerosols having droplet sizes of from 0.1 to about 3 microns in diameter. Although ultrasonic nebulizers, such as the LKB Instruments, model 108 may be used in the practice of the present invention, down draft or respiratory inhalation nebulizers of the Lovelace design are most preferred. The most preferred nebulizers of the present invention is a nebulizer used in inhalation therapy obtained from Inhalation Plastic. Inc. , model 4207, of the Lovelace design. These nebulizers are single use, disposable units that generate aerosol droplets with median mass diameters in the range of two microns. They require only a few millimeters of solution to operate efficiently and generate dense mist having up to droplets per liter of gas. Examples
Examples 1-3 are presented to demonstrate the optima range of particle sizes effective in transforming target cells in the practice of the present invention.
Examples 4-8 are presented to demonstrate the successful transformation of Chlamydomonas reinhardtii cells using the apparatus and methods of the present invention.
Aerosol Beam Microinjection of Carboxyfluorescein into Chlamydomonas reinhardtii using 2 micron mass median diameter solute/solvent droplets
Ch1amydomonas reinhardtii is a unicellular eucaryoti green alga. Cells of the wild type strain of Chlamydomonas reinhardtii (Chlamydomonas) were used as th target cells. The cells were cultured in tris-acetate- phosphate (TAP) liquid medium. (Harris, E.H. Chlamydomonas Source Book. Academic Press, 1989) . The cells were concentrated by centrifugation and resuspended in TAP at a concentration of 107 cells/ml. 100 microliters of the cell suspension were subsequently plated onto an agar medium slab containing TAP and 1.5% b weight agar for consistency. The slab also included an inert layer of Miracloth (Calbiochem, Co.) which was washed and steam autoclaved. Miracloth was included to facilitate the handling of the agar slabs. The slabs wer thereafter incubated at 25°C for from 1 to about 4 hours. Following the incubation period the slabs were chilled at 4°C for about an hour. The schematic of the apparatus used in the instant example is shown in Fig. l. The aerosol was produced by a respiratory therapy nebulizer, model 4207 obtained from Inhalation Plastic, Inc. The mass median diameter of the aerosol droplets produced by the nebulizer was 2 micrometers, according to manufacturer's literature. The nebulizing solution used was a buffered aqueous solution containing 0.01M sodium phosphate Ph 7.0 and 10 mg/ml of carboxyfluorescein. Both chemicals were obtained from the Sigma Chemical Company. The carrying gas was compressed nitrogen having a flow rate of 4 liters/min to achieve 30 psi in the nebulizer. The positive pressure created by the carrier gas was neutralized by opening the output piping of the nebulizer to the outside atmosphere. The piping leading to the vacuum housing (tubing 11 in Fig. 1) was positioned in close proximity to the open outlet piping of the nebulizer. The negative pressure in the system was created by a high-volume vacuum pump attached to the vacuum chamber. The vacuum pump used was a Marvac model R-10, set at 170 liters/min. The aerosol was accelerated into the vacuum housing through a nozzle having a diameter of 200 microns. The agar slab on which the cells were plated was placed on the target support platform, which, in turn, was positioned 1.5cm from the nozzle. The target support platform was rotated at 40 rpm, and advanced at a rate of 333 micrometers/revolution. The entire slab was scanned (impacted by carrier gas or droplets) in about 3 to 4 minutes. A control group of cells (non-impacted cells) was created on the slab by interrupting the aerosol flow in a regular pattern. Thus, the control cells on the slab are impacted with only carrier gas.
To determine the morphology of the cells impacted, the scanned slab was examined using a 4OX dissection microscope. To determine the pattern of carboxyfluorescein impact, the slab was examined using a UV Products model T-33 longwave UV transilluminator. To determine cell survival after impact, the slab was placed on a petri dish containing TAP medium and incubated for 2 days. To determine if microinjection of carboxyfluorescein had occurred in the impacted cells, th cells were removed from the slab, washed, resuspended in TAP liquid medium, and examined with a Nikon Labophot epifluorescence microscope, using a UV filter cube to observe carboxyfluorescein fluorescence.
Following scanning the slab with 2 micron droplets n intact cells were observed in the impact areas. Fluorescence was observed uniformly in all the impact areas. There was no growth in the impact area following two day incubation. Thus, it was determined that cells impacted by droplets having a mass median diameter of 2 microns or greater would not service the procedure.
Aerosol Beam Microinjection of Carboxyfluorescein into Chlamydomonas reinhardtii using 0.1 micron mass median diameter solute/solvent droplets
The protocol set forth in Example 1 was followed in Example 2 with the following exception. A drying tube wa included in the apparatus. The drying tube was located i close proximity to the nebulizer, as shown in Fig. 2. Th drying tube had an internal diameter of 1/2 inch and was 60 cm long. It contained silica gel which surrounded a central channel formed by a cylinder of 20 mesh stainless steel screening. The drying tube of the instant example was prepared by the inventor; however, similar drying tubes are available from TSI, Inc. (model 3062 Diffusion _20_
Dryer) . The solvent was completely removed by the drying tube so that only a dry aerosol of the solutes remained to be accelerated and impact the cells. Based on the mean masses of the solutes it is estimated that the impacting 5 projectiles had a mass median diameter of about 0.1 microns.
Following scanning the slab with 0.1 micron
10 projectiles, visual examination with the 40X dissection microscope revealed that all the cells in the impacted area were intact. Further, the distribution of carboxyfluorescein on the slab was uniform throughout the impact areas. Thus, demonstrating that the cells has ben
15 impacted. There was 100% cell survival after a 2 day incubation. However, no fluorescence was observed in the washed and resuspended impacted cells. This suggested that no carboxyfluorescein was successfully injected into the cells.
Aerosol Beam Microinjection of Carboxyfluorescein into Chlamydomonas reinhardtii on sorbitol containing 25 medium using 2.0 micron mass median diameter solute/solvent droplets
Example 3 followed the protocol set forth in Example 1 with the following exceptions: the agar slab included
30 0.5M sorbitol to help osmotically stabilize the impacted cells; and the cells were immediately washed and resuspended following microscopic and UV inspection of the slab. Thus, the incubation step, which determined cell survival was postponed until it was determined if
35 carboxyfluorescein had been successfully microinjected into the cells. Results
Following scanning the slab with 2 micron droplets the cells were inspected with the 4OX dissection microscope and substantially all the cells in the impact area appeared intact. Following washing and resuspension substantially all of the impacted cells contained florescent carboxyfluorescein. Thus, carboxyfluorescein was successfully microinjected into the cells. However, following subsequent replating of the impacted cells, no cell survival was below 0.1%.
Example 4 Transformation of Chlamydomonas reinhardtii Mutant D15 through the microinjection of DNA plasmid p71.
The target cells were wild type Chlamydomonas reinhardtii Mutant D15 which are incapable of growing on minimal media because of a deletion of the chloroplast tscA gene that renders them defective in photosynthesis. No spontaneous reversion of this deletion has been observed. The DNA plasmid p71 used as the genetic transforming agent carries the Ch1amydomonas reinhardtii chloroplast DNA fragment Ecolδ (Harris, E.H. Chlamydomona Source Book. Academic Press, 1989) cloned in Js, coli in the pUC8 cloning vector. It was obtained from Dr. Jane Aldrich, BP America. This fragment has the intact tscA gene that was deleted from the D15 mutant chloroplast DNA
The nebulizing solution included lO M tris-Cl pH 8.0 ImM disodium EDTA, 3mM magnesium chloride, O.lmg/ml plasmid p71, 10% polyethylene glycol 6000, and distilled water. All reagents were obtained from the Sigma Chemica Company. Polyethylene glycol and magnesium chloride are included in the solvent mixture to cause the tight condensation of the DNA, which protects it from shear degradation during aerosol formation. The effectiveness of this treatment was verified in preliminary experiments in which the aerosol generated from this solvent was recovered and the DNA analyzed by electrophoresis for intactness. In addition, it was tested for biological function by transformation of E_. coli.
The target cells were grown in TAP liquid medium and concentrated by centrifugation. The cells were plated on an agar slab and incubated as described in Example 1. Before scanning, the agar slab was placed onto a petri plate containing solidified TAP medium containing 0.5M sorbitol for two hours at room temperature and for an additional one hour at 4β C. It is believed that the presence of the sorbitol in the medium helps the cells to maintain their integrity during an osmotically sensitive period during recovery after being impacted by the projectiles.
The apparatus used in Example 4 is illustrated schematically in Fig. 2. The drying tube utilized was the same drying tube as used in Example 2. The laminar flow accounted for 50% of the total flow through the nozzle. The nozzle was 200 microns in diameter. The target cells were positioned 1.5cm from the nozzle and the procedure used for scanning the surface of the agar slab was the same as was used in Examples 1-3. The carrier gas was nitrogen and the flow rate through the drying tube was set at 160 ml/minute.
Following the scanning of the surface of the agar slab, the impacted cells were screened for the presence of transformants. The slab was transferred, to tris-minimal medium (Harris, E.H., Chlamydomonas Source Book. Academic Press, 1989) and incubated in light. Thus, only those cells which had been transformed could photosynthesize in the presence of light and survive. Following incubation for two days, two colonies were observed on the minimal medium. These colonies were removed and streaked onto petri dishes containing tris-minimal medium. Subsequently, a plurality of colonies grew. This growth test was repeated a second time after seven days.
Total cell DNA was isolated from the transformed
Ch1a vdomonas reinhardtii cells. The cells were grown to
6 a concentration of 3 X 10 cells/ml in TAP liquid medium. They were harvested by centrifugation at 5000 Xg for five g minutes and resuspended to a final concentration of 10 cells per ml in ice water buffer I (lOmM sodium chloride, lO M tris-Cl, lOmM sodium EDTA, pH 8.0). This suspension was incubated with an equal volume of ice cold 4M lithium chloride and incubated for thirty minutes. The cells wer then harvested by centrifugation as before and then washe twice with ice cold buffer I. The cell pellet obtained i the final wash was weighed and then the cells resuspended in 10 ml per gram pellet of ice cold buffer I. One third volume of 10%- (w-v) sodium dodecyl sulfate detergent was added along with 0.1 mg/ml of Pronase (Sigma). This mixture was incubated at 37° C for three hours or longer until the chlorophyll was entirely converted to pheophyti (olive-green in color) . This solution was then cooled to room temperature and extracted twice with freshly distilled phenol (the phenol was distilled, washed with one half volume of 0.5M tris base and equilibrated before use with one volume of lOmM tris-Cl pH 8.0, ImM disodium EDTA, 50mM sodium chloride ) . The aqueous phase separate from the second phenol extraction was mixed with one half volume of 7.5M ammonium acetate and then centrifuged in a micro centrifuge (Eppendorf) for one minute. The supernatant was thereafter mixed with two volumes of ethanol and placed in -70° C freezer for ten minutes. Th precipitated nucleic acids were collected by centrifugation in the micro centrifuge for one minute and the supernatant discarded. The pellet was resuspended in one tenth of TE buffer (lOmM tris-Cl, lmM disodium EDTA, pH 8.0). This ammonium acetate precipitation step was repeated once more.
The DNA obtained from the transfor ants was thereafter analyzed. One aliquot of the DNA obtained as set forth above from one of transformants was digested with restriction enzyme EcoRI, one with a combination of BamHI and Bglll and one with Smal, using the enzymes according the manufacturer's instructions (Boehringer- Mannheim) . A similar digestion was performed on DNA from wild-type cells, DNA from the D15 mutant cells, and DNA from the p71 plasmid used in the transformation experiment. The DNA fragments were separated by electrophoresis in 0.7% agarose gels using tris-borate- EDTA buffer according to standard procedures. The DNA was transferred to Nytran membranes (Schleicher and Schuell) using the standard Southern blot procedure. DNA for use as probes to detect specific fragments on the membrane was radioactively labeled by random priming, using a kit according to the manufacturer's instructions (Boehringer- Mannheim) . Probes were prepared from pUC18 plasmid DNA and from fragments of the Eco-18 chloroplast DNA isolated from the p71 plasmid.
The hybridization with the pUC probe reveals the presence of an intact pUC vector sequence in transformants. No reactivity was seen in the wild type or D15 strain DNA samples. These results demonstrate that the DNA was microinjected into the target mutant cells to produce transformants in the experiment.
While the invention is susceptible to various modifications and alternative forms, specific embodiments thereof have been shown by way of example in the drawings and have been described in detail. It should be understood, however, that it is not intended to limit the invention to the particular forms disclosed, but on the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention as defined by the appended claims.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|EP0301749A2 *||20 Jul 1988||1 Feb 1989||Agracetus, Inc.||Particle-mediated transformation of soybean plants and lines|
|1||*||BIOTECHNOLOGY vol. 6, May 1988, NEW YORK US pages 559 - 563; KLEIN, T. M. et al.: "Factors influencing gene delivery into zea mays cells by high-velocity microprojectiles" see the whole document|
|2||*||PARTICULATE SCIENCE AND TECHNOLOGY vol. 5, 1987, pages 27 - 37; SANFORD, J.C. et al.: "Delivery of substances into cells and tissues using a particle bombardment process" see pages 29 - 31; figures 1, 2|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|WO1992004439A1 *||30 Aug 1991||19 Mar 1992||Brian John Bellhouse||Ballistic apparatus|
|WO1993007256A1 *||5 Oct 1992||15 Apr 1993||Ciba-Geigy Ag||Particle gun for introducing dna into intact cells|
|WO1993023552A1 *||21 May 1993||25 Nov 1993||Government Of The United States As Represented By Secretary Department Of Health And Human Services||Targeting gene expression to living tissue using jet injection|
|WO1995033061A1 *||24 May 1995||7 Dec 1995||Boehringer Ingelheim International Gmbh||Method for introducing nucleic acid in higher eukaryotic cells|
|WO1996004947A1 *||17 Aug 1995||22 Feb 1996||Oxford Biosciences Limited||Particle delivery|
|WO2001005994A2 *||21 Jul 2000||25 Jan 2001||Immunoporation Ltd.||Method for introducing a substance into a cell|
|WO2001005994A3 *||21 Jul 2000||19 Jul 2001||Immunoporation Ltd||Method for introducing a substance into a cell|
|WO2001038514A3 *||28 Nov 2000||31 Jan 2002||Midwest Oilseeds Inc||Methods, media and apparatus for the introduction of molecules into plant cells and bacteria using aerosol beams|
|WO2002044391A3 *||28 Nov 2001||23 Jan 2003||Midwest Oilseeds Inc||Methods and compositions for the introduction of molecules into cells|
|WO2007068467A1||13 Dec 2006||21 Jun 2007||Eberhard-Karls-Universität Tübingen Universitätsklinikum||Device and method for the cultivation and production of biological material in a nutrient mist|
|WO2010075352A1||22 Dec 2009||1 Jul 2010||Athenix Corporation||Pesticidal genes from brevibacillus and methods for their use|
|WO2010075498A2||23 Dec 2009||1 Jul 2010||Athenix Corporation||Axmi-150 delta-endotoxin gene and methods for its use|
|WO2010077858A1||15 Dec 2009||8 Jul 2010||Athenix Corporation||Genes encoding nematode toxins|
|WO2010099365A2||26 Feb 2010||2 Sep 2010||Athenix Corporation||Pesticidal proteins and methods for their use|
|WO2010102172A1||5 Mar 2010||10 Sep 2010||Athenix Corporation||Methods and compositions for controlling plant pests|
|WO2010141141A2||11 Mar 2010||9 Dec 2010||Athenix Corporation||Axmi-001, axmi-002, axmi-030, axmi-035, and axmi-045: toxin genes and methods for their use|
|WO2011002992A1||1 Jul 2010||6 Jan 2011||Athenix Corp.||Axmi-205 pesticidal gene and methods for its use|
|WO2011014749A1||30 Jul 2010||3 Feb 2011||Athenix Corp.||Axmi-192 family of pesticidal genes and methods for their use|
|WO2011103247A2||17 Feb 2011||25 Aug 2011||Athenix Corp.||Axmi218, axmi219, axmi220, axmi226, axmi227, axmi228, axmi229, axmi230, and axmi231 delta-endotoxin genes and methods for their use|
|WO2011103248A2||17 Feb 2011||25 Aug 2011||Athenix Corp.||AXMI221z, AXMI222z, AXMI223z, AXMI224z, AND AXMI225z DELTA-ENDOTOXIN GENES AND METHODS FOR THEIR USE|
|WO2012135436A1||29 Mar 2012||4 Oct 2012||Athenix Corp.||Axmi238 toxin gene and methods for its use|
|WO2012135501A2||29 Mar 2012||4 Oct 2012||Athenix Corp.||Axmi232, axmi233, and axmi249 toxin genes and methods for their use|
|WO2012138703A1||4 Apr 2012||11 Oct 2012||Athenix Corp.||Axmi115 variant insecticidal gene and methods for its use|
|WO2012168124A1||30 May 2012||13 Dec 2012||Bayer Cropscience Nv||Methods and means to modify a plant genome at a preselected site|
|WO2013016617A1||27 Jul 2012||31 Jan 2013||Athenix Corp.||Axmi205 variant proteins and methods for their use|
|WO2013016622A1||27 Jul 2012||31 Jan 2013||Athenix Corp.||Axmi270 toxin gene and methods for its use|
|WO2013019600A1||27 Jul 2012||7 Feb 2013||Athenix Corp.||Axmi279 pesticidal gene and methods for its use|
|WO2013026740A2||14 Aug 2012||28 Feb 2013||Bayer Cropscience Nv||Methods and means to modify a plant genome|
|WO2013134523A1||7 Mar 2013||12 Sep 2013||Athenix Corp.||Bacillus thuringiensis toxin gene axmi335 and methods for its use|
|WO2013134535A1||7 Mar 2013||12 Sep 2013||Athenix Corp.||Axmi345 delta-endotoxin gene and methods for its use|
|WO2013134734A2||8 Mar 2013||12 Sep 2013||Vestaron Corporation||Toxic peptide production, peptide expression in plants and combinations of cysteine rich peptides|
|WO2014003769A1||29 Jun 2012||3 Jan 2014||Athenix Corp.||Axmi277 nematode toxin and methods for its use|
|WO2014036238A1||29 Aug 2013||6 Mar 2014||Athenix Corp.||Axmi-234 and axmi-235 toxin genes and methods for their use|
|WO2014126986A1||12 Feb 2014||21 Aug 2014||Athenix Corp.||Use of axmi184 for the control of rootworm insects|
|WO2014138339A2||6 Mar 2014||12 Sep 2014||Athenix Corp.||Toxin genes and methods for their use|
|WO2014150449A2||11 Mar 2014||25 Sep 2014||Bayer Cropscience Lp||Constitutive soybean promoters|
|WO2015038262A2||8 Aug 2014||19 Mar 2015||Athenix Corp.||Axmi281 toxin gene and methods for its use|
|WO2015041769A2||8 Aug 2014||26 Mar 2015||Athenix Corp.||Axmi440 toxin gene and methods for its use|
|WO2015077525A1||21 Nov 2014||28 May 2015||Bayer Cropscience Lp||Use of axmi-011 for the control of hemipteran insects|
|WO2015088937A2||8 Dec 2014||18 Jun 2015||Athenix Corp.||Axmi477, axmi482, axmi486 and axmi525 toxin genes and methods for their use|
|EP0434616A1 *||11 Dec 1990||26 Jun 1991||Ciba-Geigy Ag||Method and appliance for the genetic transformation of cells|
|EP0531506A1 *||5 Mar 1992||17 Mar 1993||Agracetus, Inc.||Particle mediated transformation of cotton|
|EP0531506A4 *||5 Mar 1992||24 Aug 1994||Agracetus||Particle mediated transformation of cotton|
|EP1818399A1 *||22 Jan 2007||15 Aug 2007||National Yang-Ming University||Methods for delivering extracellular target into cells|
|EP1947184A2||20 Feb 2004||23 Jul 2008||Athenix Corporation||Delta-endotoxin genes and methods for their use|
|EP2130839A2||3 Apr 2006||9 Dec 2009||Athenix Corporation||AXMI-027, AXMI-036 and AXMI-038, a family of delta-endotoxin genes and methods for their use|
|EP2455391A2||15 Jun 2007||23 May 2012||Athenix Corporation||A family of pesticidal proteins and methods for their use|
|EP2455392A2||15 Jun 2007||23 May 2012||Athenix Corporation||A family of pesticidal proteins and methods for their use|
|EP2455393A2||15 Jun 2007||23 May 2012||Athenix Corporation||A family of pesticidal proteins and methods for their use|
|EP2455394A2||15 Jun 2007||23 May 2012||Athenix Corporation||A family of pesticidal proteins and methods for their use|
|EP2666866A2||5 Mar 2010||27 Nov 2013||Athenix Corporation||Methods and compositions for controlling plant pests|
|EP2671951A2||22 Dec 2009||11 Dec 2013||Athenix Corporation||Pesticidal genes from Brevibacillus and methods for their use|
|EP2727933A1||25 Jun 2009||7 May 2014||Athenix Corporation||Toxin genes and methods for their use|
|EP2728006A2||10 Oct 2008||7 May 2014||Athenix Corporation||Synthetic genes encoding CRY1AC|
|EP2728007A2||5 Feb 2010||7 May 2014||Athenix Corporation||Variant Axmi-R1 delta-endotoxin genes and methods for their use|
|EP2937419A2||17 Feb 2011||28 Oct 2015||Athenix Corp.||Axmi221z, axmi222z, axmi223z, axmi224z, and axmi225z delta-endotoxin genes and methods for their use|
|EP2949659A1||2 Jul 2009||2 Dec 2015||Athenix Corporation||AXMI-115, AXMI-113, AXMI-005, AXMI-163 and AXMI-184: insecticidal proteins and methods for their use|
|EP2957638A1||26 Feb 2010||23 Dec 2015||Athenix Corporation||Pesticidal proteins and methods for their use|
|EP3150625A2||15 Jun 2007||5 Apr 2017||Athenix Corporation||A family of pesticidal proteins and methods for their use|
|EP3181579A1||16 Oct 2008||21 Jun 2017||Athenix Corporation||Axmi-066 and axmi-076: delta-endotoxin proteins and methods for their use|
|US5141131 *||28 Dec 1990||25 Aug 1992||Dowelanco||Method and apparatus for the acceleration of a propellable matter|
|US5877023 *||7 Jun 1995||2 Mar 1999||Novartis Finance Corp.||Process and apparatus for the genetic transformation of cells|
|US5965404 *||24 May 1995||12 Oct 1999||Boehringer Ingelheim International Fmbh||Method for introducing nucleic acids into higher eukaryotic cells|
|US5976880 *||18 Dec 1990||2 Nov 1999||Novartis Finance Corporation||Process and apparatus for the genetic transformation of cells|
|US5998382 *||2 May 1995||7 Dec 1999||The United States Of America As Represented By The Department Of Health And Human Services||Targeting gene expression to living tissue using jet injection|
|US6093557 *||5 Jun 1998||25 Jul 2000||Regents Of The University Of Minnesota||Electrospraying apparatus and method for introducing material into cells|
|US6361991||2 Nov 1999||26 Mar 2002||The United States Of America As Represented By The Department Of Health And Human Services||Targeting gene expression to living tissue using jet injection|
|US6399362||23 May 2000||4 Jun 2002||Regents Of The University Of Minnesota||Electrospraying apparatus and method for introducing material into cells|
|US6562623||21 Jul 2000||13 May 2003||Immunoporation Ltd||Method for introducing a substance into a cell|
|US6730663||2 Jan 2002||4 May 2004||The United States Of America As Represented By The Department Of Health And Human Services||Targeting gene expression to living tissue using jet injection|
|US6746869||3 Jun 2002||8 Jun 2004||Regents Of The University Of Minnesota||Electrospraying apparatus and method for coating particles|
|US6764720||16 May 2001||20 Jul 2004||Regents Of The University Of Minnesota||High mass throughput particle generation using multiple nozzle spraying|
|US6809232||28 Nov 2000||26 Oct 2004||Midwest Oilseeds, Inc.||Methods and compositions for the introduction of molecules into cells|
|US7207967||13 Feb 1997||24 Apr 2007||Powderject Research Limited||Particle delivery|
|US7314969||3 Feb 2004||1 Jan 2008||Midwest Oilseeds, Inc.||Methods and compositions for the introduction of molecules into cells|
|US7638115||13 Oct 2005||29 Dec 2009||Midwest Oilseeds, Inc.||Methods and compositions for the introduction of molecules into cells|
|US7638332||12 Dec 2003||29 Dec 2009||Bioware Technology Co., Ltd.||Low pressure gas accelerated gene gun|
|US9040816||10 Dec 2007||26 May 2015||Nanocopoeia, Inc.||Methods and apparatus for forming photovoltaic cells using electrospray|
|US9050611||15 Feb 2013||9 Jun 2015||Regents Of The University Of Minnesota||High mass throughput particle generation using multiple nozzle spraying|
|US9108217||31 Jan 2008||18 Aug 2015||Nanocopoeia, Inc.||Nanoparticle coating of surfaces|
|US9248217||31 Jan 2007||2 Feb 2016||Nanocopocia, LLC||Nanoparticle coating of surfaces|
|US9567381||8 Mar 2013||14 Feb 2017||Vestaron Corporation||Toxic peptide production, peptide expression in plants and combinations of cysteine rich peptides|
|US9642694||22 Dec 2014||9 May 2017||Regents Of The University Of Minnesota||Device with electrospray coating to deliver active ingredients|
|US9670496||7 Mar 2014||6 Jun 2017||Bayer Cropscience N.V.||Methods and means to modify a plant genome|
|International Classification||C12M3/00, C07K4/08, C12N15/87|
|Cooperative Classification||C12M35/04, C12M35/00, C12N15/87|
|European Classification||C12M35/00, C12N15/87, C07K4/08|
|24 Jan 1991||AL||Designated countries for regional patents|
Kind code of ref document: A1
Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB IT LU ML MR NL SE SN TD TG
|24 Jan 1991||AK||Designated states|
Kind code of ref document: A1
Designated state(s): AT AU BB BG BR CA CH DE DK ES FI GB HU JP KP KR LK LU MC MG MW NL NO RO SD SE SU
|13 Jan 1992||WWE||Wipo information: entry into national phase|
Ref document number: 1990917903
Country of ref document: EP
|2 Apr 1992||REG||Reference to national code|
Ref country code: DE
Ref legal event code: 8642
|29 Apr 1992||WWP||Wipo information: published in national office|
Ref document number: 1990917903
Country of ref document: EP
|11 May 1992||NENP||Non-entry into the national phase in:|
Ref country code: CA
|4 May 1995||WWW||Wipo information: withdrawn in national office|
Ref document number: 1990917903
Country of ref document: EP